Med. praxi. 2011;8(6):293-297
Treatment of pain and inflammation in rheumatic diseases and the role of a general practitioner
- Revmatologický ústav Praha
To explain the principles of pain treatment in rheumatic diseases, the author has chosen to present the cases of four specific patients
from his practice that have been diagnosed with rheumatoid arthritis, ankylosing spondylitis, gouty arthritis and osteoarthritis. These
are the most commonly diagnosed conditions the treatment of which may be used as a model for a number of related disease entities.
The mainstay of pain treatment in rheumatoid arthritis and ankylosing spondylitis is to effectively suppress inflammatory activity, most
commonly by combining low doses of glucocorticoid, a disease-modifying antirheumatic drug (DMARD) and/or a biological agent.
When the pain persists, nonsteroidal anti-inflammatory drugs (NSAIDs) and analgesics are administered. In a gout attack, however,
NSAIDs are the first-choice drugs from the onset of disease. In osteoarthritis, nonpharmacological and pharmacological approaches
are combined. Paracetamol is the first-choice drug followed by locally and systemically administered NSAIDs and/or symptomatic slowacting
drugs in osteoarthritis (SYSADOA).
Keywords: pain, rheumatic diseases, analgesics, nonsteroidal antirheumatic drugs
Published: July 1, 2011 Show citation
References
- Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid Arthritis Classification Criteria An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Ann Rheum Dis 2010; 69: 1580-1588.
Go to original source... 
Go to PubMed... - Prevoo ML, van-t Hof MA, Kjuper HH, et al. Modified disease activity index scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-48. Go to original source... Go to PubMed...
- Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010; 69: 964-975. Go to original source... Go to PubMed...
- Combe B, Landewe R, Lukas C, et al. EULAR recommendations for the management of early arthritis: report of a task force of ESCISIT. Ann Rheum Dis 2005; 52: 27-35.
- Sieper J, Rudwaleit M, Baraliakos X, et al. The Assessment of Spondylo-Arthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis 2009; 68(Suppl II): ii1-ii44. Go to original source... Go to PubMed...
- Pavelka K. Časná diagnostika ankylozující spondylitidy. Vnitřní lékařství 2006; 52: 7(8): 726.
- Zochling J, van der Heide D, Burgos Vargas R, et al. ASA/ EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006; 65: 442-445. Go to original source... Go to PubMed...
- Wallace SL, Robinson H, Masi AT, et al. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977; 20: 895-900. Go to original source... Go to PubMed...
- Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout-part ii management: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 2006; 25: 1301-1311. Go to original source... Go to PubMed...
- Pavelka K, Gatterová J, Olejárová M, et al. Glucosamin sulphate use and delay of progression of knee osteoarthritis. Arch Intern Med 2002; 162: 2113-2123. Go to original source... Go to PubMed...
- Richy F, Bruyere O, Ethgen O, et al. Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. Arch Intern Med 2003; 163: 1514-1522. Go to original source... Go to PubMed...
- Bellamy N, Campbal J, Robinson V, et al. Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev 2006. April 19/2/: CD005321. Go to original source...
- Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis. Part II. OARSI evidence based, expert consensus guidelines. Osteoarthritis Cart. 2008; 16: 137-162. Go to original source... Go to PubMed...
- Hawkey CJ, Karrasch JA, Szepanski L, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal anti-inflammatory drugs. N Engl J Med 1998; 338: 727-734. Go to original source... Go to PubMed...
- Schnitzler TJ, Burmestr GR, Mysler E, et al. Lumiracoxib with naproxen and ibuprofen in the therapeutic research and gastrointestinal trial (TARGET), reduction in ulcer complications, randomized controlled trial. Lancet 2004; 364: 665-674. Go to original source... Go to PubMed...
- Grosser T, Fries S, Fitz Gerald: Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 2006; 116: 4-15. Go to original source... Go to PubMed...
- Pavelka K, Trč T, Karpat K, et al. The efficacy and safety of diacerein in the treatment of painful osteoarthritis of the knne. A randomized, multicenter, double-blind, placebo-controlled study with primary end points at two months after the end of three-month treatment period. Arthritis Rheumatism 2007; 56(12): 4055-4064. Go to original source... Go to PubMed...
- Wandel S, Jüni P, Tendal B, et al. Effects of glucocamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. BMJ 2010; 341: 1-9. doi: 10.1136/bmj.c4675. Go to original source... Go to PubMed...
- Avouac J, Gossec L, Dougados M, et al. Efficacy and safety of opioids for osteoarthritis: a metaanalysis of randomized controlled trials. Osteoarthritis Cart 2007; 15: 957-965. Go to original source... Go to PubMed...